NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD
Overall LXRX gets a fundamental rating of 2 out of 10. We evaluated LXRX against 567 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LXRX is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -67.15% | ||
ROE | -137.31% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 98.02% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.69 | ||
Debt/FCF | N/A | ||
Altman-Z | -9.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.44 | ||
Quick Ratio | 5.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.7084
+0.01 (+0.71%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 8.24 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.75 | ||
P/tB | 2.53 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -67.15% | ||
ROE | -137.31% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 98.02% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.69 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 193.07% | ||
Cap/Sales | 3.32% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.44 | ||
Quick Ratio | 5.44 | ||
Altman-Z | -9.5 |